HLA-matched allo-SCT after reduced intensity conditioning with fludarabine/CY in patients with metastatic breast cancer

Stijn A. J. H. M. Fleskens; R. I. Lalisang; G. M. J. Bos; M. van Gelder; R. L. H. Jansen; H. C. Schouten

doi:10.1038/bmt.2009.178

HLA-matched allo-SCT after reduced intensity conditioning with fludarabine/CY in patients with metastatic breast cancer

Stijn A. J. H. M. Fleskens, R. I. Lalisang, G. M. J. Bos, M. van Gelder, R. L. H. Jansen, H. C. Schouten^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Fifteen patients with chemosensitive metastatic breast cancer (MBC) underwent reduced intensity (RIST) alloSCT between 1999 and 2006. The purpose of this single-center study was to evaluate the feasibility, safety and efficacy of this therapeutic approach. The pretransplant conditioning regimen consisted of fludarabine (25 mg/m(2) at days -5 to -1) and CY (60 mg/kg at days -2, -1). Stem cells were from HLA-matched sibling donors. The treatment-related mortality was 2/15 (13%). Median PFS and OS were 144 days (43-509 days) and 303 days (122-1376 days), respectively. The 1-year PFS was 20%, and the 1-year and 2-year OS was 40 and 20%, respectively. No objective tumor responses were observed, but the relatively long PFS does suggest a graft-vs-tumor effect. Although RIST using this CY/fludarabine regimen is feasible, the efficacy in this set of patients was limited. Future clinical trials should be performed to improve the knowledge of mechanisms of antitumor effects in breast cancer.

Original language	English
Pages (from-to)	464-467
Journal	Bone Marrow Transplantation
Volume	45
Issue number	3
DOIs	https://doi.org/10.1038/bmt.2009.178
Publication status	Published - Mar 2010

Keywords

reduced intensity transplants
RIST
metastatic breast cancer
phase II study

Access to Document

10.1038/bmt.2009.178

Cite this

@article{d53765a547804837a75d5371ec54dfb8,

title = "HLA-matched allo-SCT after reduced intensity conditioning with fludarabine/CY in patients with metastatic breast cancer",

abstract = "Fifteen patients with chemosensitive metastatic breast cancer (MBC) underwent reduced intensity (RIST) alloSCT between 1999 and 2006. The purpose of this single-center study was to evaluate the feasibility, safety and efficacy of this therapeutic approach. The pretransplant conditioning regimen consisted of fludarabine (25 mg/m(2) at days -5 to -1) and CY (60 mg/kg at days -2, -1). Stem cells were from HLA-matched sibling donors. The treatment-related mortality was 2/15 (13%). Median PFS and OS were 144 days (43-509 days) and 303 days (122-1376 days), respectively. The 1-year PFS was 20%, and the 1-year and 2-year OS was 40 and 20%, respectively. No objective tumor responses were observed, but the relatively long PFS does suggest a graft-vs-tumor effect. Although RIST using this CY/fludarabine regimen is feasible, the efficacy in this set of patients was limited. Future clinical trials should be performed to improve the knowledge of mechanisms of antitumor effects in breast cancer.",

keywords = "reduced intensity transplants, RIST, metastatic breast cancer, phase II study",

author = "Fleskens, {Stijn A. J. H. M.} and Lalisang, {R. I.} and Bos, {G. M. J.} and {van Gelder}, M. and Jansen, {R. L. H.} and Schouten, {H. C.}",

year = "2010",

month = mar,

doi = "10.1038/bmt.2009.178",

language = "English",

volume = "45",

pages = "464--467",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - HLA-matched allo-SCT after reduced intensity conditioning with fludarabine/CY in patients with metastatic breast cancer

AU - Fleskens, Stijn A. J. H. M.

AU - Lalisang, R. I.

AU - Bos, G. M. J.

AU - van Gelder, M.

AU - Jansen, R. L. H.

AU - Schouten, H. C.

PY - 2010/3

Y1 - 2010/3

N2 - Fifteen patients with chemosensitive metastatic breast cancer (MBC) underwent reduced intensity (RIST) alloSCT between 1999 and 2006. The purpose of this single-center study was to evaluate the feasibility, safety and efficacy of this therapeutic approach. The pretransplant conditioning regimen consisted of fludarabine (25 mg/m(2) at days -5 to -1) and CY (60 mg/kg at days -2, -1). Stem cells were from HLA-matched sibling donors. The treatment-related mortality was 2/15 (13%). Median PFS and OS were 144 days (43-509 days) and 303 days (122-1376 days), respectively. The 1-year PFS was 20%, and the 1-year and 2-year OS was 40 and 20%, respectively. No objective tumor responses were observed, but the relatively long PFS does suggest a graft-vs-tumor effect. Although RIST using this CY/fludarabine regimen is feasible, the efficacy in this set of patients was limited. Future clinical trials should be performed to improve the knowledge of mechanisms of antitumor effects in breast cancer.

AB - Fifteen patients with chemosensitive metastatic breast cancer (MBC) underwent reduced intensity (RIST) alloSCT between 1999 and 2006. The purpose of this single-center study was to evaluate the feasibility, safety and efficacy of this therapeutic approach. The pretransplant conditioning regimen consisted of fludarabine (25 mg/m(2) at days -5 to -1) and CY (60 mg/kg at days -2, -1). Stem cells were from HLA-matched sibling donors. The treatment-related mortality was 2/15 (13%). Median PFS and OS were 144 days (43-509 days) and 303 days (122-1376 days), respectively. The 1-year PFS was 20%, and the 1-year and 2-year OS was 40 and 20%, respectively. No objective tumor responses were observed, but the relatively long PFS does suggest a graft-vs-tumor effect. Although RIST using this CY/fludarabine regimen is feasible, the efficacy in this set of patients was limited. Future clinical trials should be performed to improve the knowledge of mechanisms of antitumor effects in breast cancer.

KW - reduced intensity transplants

KW - RIST

KW - metastatic breast cancer

KW - phase II study

U2 - 10.1038/bmt.2009.178

DO - 10.1038/bmt.2009.178

M3 - Article

C2 - 19633692

SN - 0268-3369

VL - 45

SP - 464

EP - 467

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 3

ER -